Isotretinoin is an oral drug for severe acne, and the 2026 maintenance trial followed 60 cleared adults to test weekend dosing against relapse. Patients were 18 or older with moderate-to-severe facial acne in Alexandria; teens, mild or body acne, pregnancy, acne drugs, and endocrine disease were not studied.
Cumulative dose means total milligrams per kilogram taken across a course. The small trial compared weekend isotretinoin with alternate-day adapalene for one year after clearance. A much larger 2026 cohort then linked each extra milligram per kilogram to slightly lower relapse risk.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How did the Alexandria maintenance trial work?
- Who was not studied?
- What did dose and relapse results show?
- What should adults with persistent acne check next?
How did the Alexandria maintenance trial work?
Alexandria University sponsored the Phase 3 trial NCT06451237. It tested weekend oral isotretinoin to keep patients free of lesions after a full daily course had produced total control, according to inClinicalTrials. The ICH GCP Registry describes three maintenance paths after initial treatment.
Groups A and B had received 120-150 mg/kg in total, while Group C continued until clearance plus one extra month. Group A then used alternate-day adapalene, Groups B and C used weekend isotretinoin, and all had one-year relapse follow-up. The enrolled group was 60 adults age 18 and older with moderate-to-severe facial acne by Investigator Global Assessment in Alexandria, Egypt, with no healthy volunteers, according to the Veeva Clinical Trial Viewer summary.
Who was not studied?
The trial excluded several common adult situations. The Veeva viewer, using clinicaltrials.gov data, lists these exclusions: That matters because persistent adult acne often overlaps with hormones, pregnancy planning, or combination therapy.
The design was also narrow: 60 adults, one center, facial acne only, and 12 months of follow-up. The journal authors state that design does not establish effects for adolescents, mild or truncal acne, or endocrine-related disease.
- systemic acne drugs in the prior 3 months
- topical acne drugs in the prior month
- pregnant or breastfeeding females
- endocrine disturbances or medications taken for other health conditions
What did dose and relapse results show?
In the 60-patient report, relapse occurred in 85% on adapalene maintenance versus 35% and 45% on the two weekend-isotretinoin arms. Time to relapse was significantly shorter after adapalene, with no significant difference between the two weekend-isotretinoin groups, according to the Journal of the Egyptian Women's Dermatologic Society report via Ovid.
A larger claims cohort of 19,907 patients age 12 and older found each extra mg/kg lowered relapse risk with a hazard ratio of 0.996. Higher daily dose added no benefit after 120 mg/kg, with no added signal beyond 220 mg/kg, as reported by Dermatology Times covering the JAMA Dermatology study. Practically, the Egyptian journal authors concluded low-dose weekend isotretinoin was better tolerated than initial daily treatment for maintaining adult remission.
What should adults with persistent acne check next?
Use the trial boundaries as a personal checklist before asking about maintenance. The studied pattern was adult, moderate-to-severe, facial acne that had fully cleared on daily isotretinoin.
Bring a full drug list, acne timeline, prior total dose if known, and pregnancy plans to a dermatology visit. Ask whether weekend maintenance fits your history, what relapse signs to watch, and what follow-up interval makes sense for 12 months after clearance.
- cleared facial acne after a full course, not active severe disease
- age 18 or older
- no recent systemic or topical acne drugs by trial windows
- no current pregnancy, planned pregnancy, or breastfeeding
- no endocrine disorder and no ongoing drugs for other conditions
You Might Also Like
- Cumulative Isotretinoin Dose and Acne Relapse in a 2026 Trial: Safety and Monitoring Questions for Adults With Persistent Acne
- Treatment Response in the 2026 Cumulative Isotretinoin Dose Trial: What the Findings Mean for Adults With Persistent Acne
- Why the 2026 Probiotic and Secretome Paper Reports No Trial Results Yet: How Adults With Persistent Acne Can Avoid Microbiome Hype